Lahdan Refahiyat, MD
Interventional Cardiology · Carson City, NVNPI 1801246731
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (52.5%), grants and education — rather than concentrated in one kind of arrangement. 18 manufacturers reported payments, led by Medtronic at 48.8% of the total. Reporting peaked in 2022 at $4,883 and has fallen 64.8% since, to $1,720 in 2025. That places this record below the midpoint for interventional cardiology clinicians in NV, where the typical reported total is $9,708.
Across 159 payments — averaging $54.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$4K
- Boston Scientific$1K
- Abbott$1K
- Shockwave Medical, Inc$945
- Abiomed$302
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$77
- plus $529 from 12 others
What the payments were for
- Grants$4,00046%
- Food & beverage$4,58653%
- Education$1442%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 3 | $4,258 |
| Boston Scientific | 80 | $1,451 |
| Abbott | 29 | $1,169 |
| Shockwave Medical, Inc | 15 | $945 |
| Abiomed | 6 | $302 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $77 |
| Pfizer | 4 | $76 |
| E.r. Squibb & Sons, L.L.C. | 3 | $69 |
| Biosense Webster, Inc. | 2 | $59 |
| Amgen | 3 | $54 |
| Johnson & Johnson | 2 | $47 |
| Boehringer Ingelheim | 2 | $45 |
| Novartis | 2 | $42 |
| Teleflex LLC | 2 | $42 |
| Acist Medical Systems, Inc. | 1 | $32 |
| Lexicon Pharmaceuticals, Inc. | 1 | $22 |
| Regeneron Healthcare Solutions, Inc. | 1 | $22 |
| Cardiva Medical, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,731 in reported general payments places this provider in the 40th percentile of 62 interventional cardiology providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 155 | $146,941 |
| XareltoRivaroxaban | 106 | $76,392 |
| Rosuvastatin Calcium | 192 | $4,472 |
| Atorvastatin Calcium | 188 | $2,443 |
| Ezetimibe | 47 | $2,295 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 12 | $1,909 |
| Metoprolol Succinate | 123 | $1,291 |
| Losartan Potassium | 123 | $1,268 |
| Amlodipine Besylate | 136 | $1,064 |
| Carvedilol | 86 | $825 |
| Potassium Chloride | 17 | $547 |
| Metoprolol Tartrate | 107 | $522 |
| Flecainide Acetate | 12 | $518 |
| ClopidogrelClopidogrel Bisulfate | 46 | $505 |
| Warfarin Sodium | 34 | $473 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $76 | $146,941155 claims |
| Johnson & JohnsonXarelto | $47 | $76,392106 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 62 interventional cardiology providers in Nevada.
Other interventional cardiology in Carson City
- Nathan HoCarson City$19K
- Mithun DevrajCarson City$15K
- Cres MirandaLas Vegas$660K
- Jeffrey LevismanHenderson$226K
- Howard BroderHenderson$168K
- Adrian Mercado-AlamoLas Vegas$118K
- Nayab ZafarLas Vegas$102K
- William ChuLas Vegas$75K
- Karthiek NaralaHenderson$44K
- Neville MistryLas Vegas$36K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.